Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

61.18 +0.31 (+0.51%)

Official Closing Price Updated: 7:00 PM EST, Feb 18, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	5,390,011
Open	61.54
Bid (Size)	61.45 (100)
Ask (Size)	61.84 (200)
Prev. Close	60.87
Today's Range	60.98 - 61.70
52wk Range	32.38 - 61.70
Shares Outstanding	5,385,189,617
Dividend Yield	2.73%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows

February 18, 2026

From GSK plc

Via Business Wire

Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline

February 17, 2026

As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based...

Via Finterra

Performance

YTD	+23.3%	+23.3%
1 Month	+28.4%	+28.4%
3 Month	+32.0%	+32.0%
6 Month	+52.7%	+52.7%
1 Year	+67.1%	+67.1%

More News

Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results

February 13, 2026

Via MarketMinute

The Great 2026 Divergence: Tech Titans Rise on AI Execution While Healthcare Reaps a Regulatory Whirlwind

February 13, 2026

Via MarketMinute

FDA Stuns Moderna with Refusal to Review Flu Vaccine, Sending Shares Tumbling 3.5%

February 12, 2026

Via MarketMinute

Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss

February 11, 2026

Via Finterra

Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse

February 10, 2026

Via Finterra

GSK (GSK) Q3 2025 Earnings Call Transcript ↗

February 05, 2026

Via The Motley Fool

The Great Consolidation: US M&A Values Double as AI and Bio-Pharma Spark $2 Trillion Surge

January 26, 2026

Via MarketMinute

Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse

January 22, 2026

Via Finterra

GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026

January 21, 2026

From GSK plc

Via Business Wire

Why Rapt Therapeutics Stock Soared Today ↗

January 20, 2026

Via The Motley Fool

AstraZeneca Signals End of an Era: Formal Move to NYSE Triggers Major Index Rebalancing

January 20, 2026

Via MarketMinute

The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion

January 20, 2026

Via MarketMinute

GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics

January 20, 2026

Via MarketMinute

GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million

January 20, 2026

From GSK plc

Via Business Wire

Why Did RAPT Stock Surge 63% In Pre-Market Today? ↗

January 20, 2026

Via Stocktwits

The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026

January 16, 2026

Via Finterra

Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot

January 14, 2026

Via Finterra

The Tariff Paradox: How Trump's 'Liberation Day' Protectionism Sparked a $2.3 Trillion M&A Feeding Frenzy

January 13, 2026

Via MarketMinute

The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape

January 12, 2026

Via MarketMinute

BioNTech Finalizes CureVac Acquisition: A Strategic Consolidation Met with Market Skepticism

January 09, 2026

Via MarketMinute

Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics

January 09, 2026

Via PredictStreet

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗

January 08, 2026

Via Stocktwits

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

Via MarketMinute

Frequently Asked Questions

Is GSK plc American Depositary Shares (Each representing two Ordinary Shares) publicly traded?

Yes, GSK plc American Depositary Shares (Each representing two Ordinary Shares) is publicly traded.

What exchange does GSK plc American Depositary Shares (Each representing two Ordinary Shares) trade on?

GSK plc American Depositary Shares (Each representing two Ordinary Shares) trades on the New York Stock Exchange

What is the ticker symbol for GSK plc American Depositary Shares (Each representing two Ordinary Shares)?

The ticker symbol for GSK plc American Depositary Shares (Each representing two Ordinary Shares) is GSK on the New York Stock Exchange

What is the current price of GSK plc American Depositary Shares (Each representing two Ordinary Shares)?

The current price of GSK plc American Depositary Shares (Each representing two Ordinary Shares) is 61.18

When was GSK plc American Depositary Shares (Each representing two Ordinary Shares) last traded?

The last trade of GSK plc American Depositary Shares (Each representing two Ordinary Shares) was at 02/18/26 07:00 PM ET

What is the market capitalization of GSK plc American Depositary Shares (Each representing two Ordinary Shares)?

The market capitalization of GSK plc American Depositary Shares (Each representing two Ordinary Shares) is 329.47B

How many shares of GSK plc American Depositary Shares (Each representing two Ordinary Shares) are outstanding?

GSK plc American Depositary Shares (Each representing two Ordinary Shares) has 329B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.